Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

NLS Pharmaceutics and Kadimastem announce a $500,000 initial closing of a $1 million fundraising, with shares priced at $3.10, a 48% premium over the January 6, 2025 market price

NLS Pharmaceutics Ltd. a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. "Kadimastem", a clinical-stage cell...

Cardurion Pharmaceuticals has named Charlotte Newman as Chief Business Officer

Cardurion Pharmaceuticals, Inc. a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as...

PBS Biotech Secures $17M and Expands Leadership to Accelerate Next-Gen Cell Therapies

PBS Biotech ("PBS"), a provider of innovative single-use bioreactor systems and bioprocess development services, has secured $17 million in follow-on growth capital from Avego Management, LLC ("Avego") and BroadOak Capital Partners ("BroadOak")....

Genesis Medtech secures Chinese approval for its groundbreaking 90° articulation powered surgical stapler, setting new standards in precision surgery

Genesis Medtech is proud to announce that iReach Omnia, the world's first powered stapler with 90° articulation capability, has been approved for market release in China by the National Medical Products Administration (NMPA). Independently...

"Fresenius Kabi expands its U.S. pharma portfolio with the launch of Epinephrine Injection, USP

Fresenius Kabi, an operating company of Fresenius, announced that Epinephrine Injection, USP, is now available in the United States as the first generic version of Epinephrine in a 1mg/1mL vial for U.S. customers. Epinephrine Injection, USP is a...

To advance the first oral therapy for BK Polyomavirus, Orthogon Therapeutics closes an oversubscribed $5.2M financing

Orthogon Therapeutics, a developer of novel antiviral medicines, announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing total funding to over $25M. This funding will accelerate the development of its...

Isotopia collaborates with LIVEKIDNEY.BIO, marking a breakthrough in lupus treatment advancements

Isotopia is proud to announce a groundbreaking partnership with LIVEKIDNEY.BIO, a clinical-stage biotech innovator, to support the development of a critical component for its revolutionary lupus nephritis therapy. This collaboration offers the...

ADC Therapeutics shares promising initial LOTIS-7 trial data on ZYNLONTA® combined with a bispecific antibody for relapsed/refractory DLBCL.

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), announced positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy...

Pilatus Biosciences Inc. earns FDA Orphan Drug Designation for PLT012, targeting liver and intrahepatic bile duct cancer

Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Achieved in November...

Biolexis Therapeutics reports positive outcomes for BLX-7006 in an expanded Diet-Induced Obesity (DIO) model study

Biolexis Therapeutics, a leading metabolic drug discovery company focused on improving the lives of patients with chronic metabolic conditions, including obesity, diabetes, and related diseases, announced the successful completion of an expanded...

UroMems Appoints Former Axonics Executive Rinda Sama to Board of Directors

UroMems, a global medical technology company developing the first smart automated implant to treat stress urinary incontinence (SUI), today announced the appointment of medical device veteran Rinda Sama to its board of directors. "We are thrilled...

Children’s Hospital Los Angeles completes its 100th retinal gene therapy procedure, advancing pediatric vision care.

His newly treated patients might show significant improvements on their eye chart tests, but Aaron Nagiel, MD, PhD, will tell you that the truest signs of visual progress come through the texts he receives from parents days, weeks, and months...

Leqembi® approved in Mexico

BioArctic AB's partner Eisai announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of early Alzheimer's disease (AD)1. Leqembi selectively binds to...

Phanes Therapeutics' PT217 receives FDA Fast Track Designation for neuroendocrine prostate cancer (NEPC)

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PT217 for...

SciTech Development reveals promising Phase 1A trial results for T-cell non-Hodgkin lymphoma therapy

SciTech Development, a clinical-stage pharmaceutical company focused on advancements in cancer treatment, is excited to share promising updates from its clinical trial of ST-001 nanoFenretinide (ST-001). Preliminary Trial Findings: Preliminary...

Dr. Jonathan Sadeh, ex-SVP of Immunology R&D at Bristol-Myers Squibb, joins Scinai Immunotherapeutics' Scientific Advisory Board

Scinai Immunotherapeutics Ltd. a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced that Dr. Jonathan Sadeh has...

NS Pharma announces a leadership change, appointing new commercial head to drive strategic growth and innovation

NS Pharma, Inc. announced a change of leadership within its Commercial division. Effective September 9, 2024, Donald Foy – who had previously served as national sales director – was appointed to the role of vice president, Commercial. Jennifer...

Niterra Ventures invests an additional $18M in Neoplas Med GmbH, supporting advancements in innovative cancer therapies

Greifswald-based medical technology pioneer Neoplas Med GmbH is intensifying its strategic collaboration with Niterra Ventures Company, via an $18M capital increase to expand the market further for innovative wound care technology products. With a...

Hanmi Pharmaceutical and Beijing Hanmi advance clinical trials for BH3120, their co-developed next-generation cancer immunotherapy

The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical, was recently presented at a major global academic conference, drawing significant...

A Korea University study identifies mitochondrial dysfunction as a key factor in cognitive and metabolic impairments, offering insights into potential treatments

Animal models expressing loss-of-function mutations in mitochondrial DNA enable the investigation of mitochondrial gene function and related disorders. In a recent study, scientists from Korea University described the impact of a mitochondrial ND5...